Effectiveness and Safety of Adalimumab, Etanercept and Ustekinumab for Severe Psoriasis in Children Under 12 Years of Age: A French-Italian Daily Practice Cohort (BiPe Jr)

0 avis

Effectiveness and Safety of Adalimumab, Etanercept and Ustekinumab for Severe Psoriasis in Children Under 12 Years of Age: A French-Italian Daily Practice Cohort (BiPe Jr)

Archive ouverte

Edité par CCSD ; Springer Verlag -

International audience

Langue: en

Consulter en ligne

Consulter le document

Suggestions

Du même auteur

Biomédicaments dans le psoriasis de l’enfant de moins de 12 ans. Cohorte rétrospective Franco-Italienne

Archive ouverte | Zitouni, Jinane | CCSD

International audience. IntroductionL’utilisation des biomédicaments est indiquée dans les formes modérées à sévères du psoriasis chez l’adulte et l’enfant. Jusqu’en 2020, 2 biomédicaments étaient autorisés avant 12...

Effectiveness of biologic therapies in children with palmoplantar plaque psoriasis: An analysis of real‐life data from the BiPe cohorts

Archive ouverte | Hanafi, Bochra | CCSD

International audience. Abstract Background Palmoplantar plaque psoriasis is a frequent clinical subtype of childhood psoriasis. This study evaluated the effectiveness of biologic therapies in children with palmopla...

Switching biologics in children with psoriasis: Results from the BiPe cohort

Archive ouverte | Phan, Céline | CCSD

International audience

Chargement des enrichissements...